A new study has identified independent risk factors for the development of non-Hodgkin lymphoma (NHL) including high fetal growth, older age of the mother, low birth order, and male sex. A family history of NHL in either parent...

The top three most clinically relevant updates of 2012. Interactive format, with chances to interact with peers and presenters. Covering nine tumor sites! Join us for a great day - registration now

An abstract presented at the 13th Annual Meeting of the American Society of Breast Surgeons, “Biology, Not Choice of Mastectomy versus Lumpectomy, Dictates Recurrence in High-Risk Breast Cancer,” suggests that women who are at...

Clinical Debate Series: Emerging Evidence in Treating Patients with Refractory CLL: Introduction. Peter Hilman et al.

New data presented at the 13th Annual Meeting of the American Society of Breast Surgeons shows radiofrequency ablation can prevent local breast cancer recurrence just as effectively as radiation therapy. Compared to radiation...

The top three most clinically relevant updates of 2012. Interactive format, with chances to interact with peers and presenters. Covering nine tumor sites! Join us for a great day - registration now

Results from a phase II clinical trial with HSPPC-96 (vitespen), an autologous heat shock protein-peptide vaccine, have shown promise in patients with recurrent glioblastoma multiforme. The results were presented last week in...

Artemend Breast Microseed Treatment is a form of partial breast radiation treatment. It is a single, one-hour treatment for early stage breast cancers. It’s success has been proven through clinical studies with over 7-year...

Of all the sad pronouncements that oncologists deliver, this may be the one that stings the most. If you were expecting hope from your doctor, how would you react to these words? Would you sit with quiet disbelief, or storm out of the office?

This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin), a first-in-class, highly targeted and well-tolerated alpha-pharmaceutical under development to improve

Though the calcium-dependent chloride channel DOG1 is strongly expressed in gastrointestinal stromal tumors (GIST), a new laboratory study suggests that methods targeting it for therapies in treating these cancers are still a...

Scotland will soon begin a large prospective trial of early screening for lung cancer in high-risk patients using a simple blood test. The test, called EarlyCDT-Lung, has been in use and trials in the United States for more...

CLEVELAND -- Researchers at Case Western Reserve University School of Medicine have identified a "switch" that appears to allow for the development of colon cancer. Researchers focused on segments of DNA between genes and found...

Vemurafenib (Zelboraf) was approved in August 2011 for metastatic melanoma patients whose tumors harbor the V600 mutation in the BRAF gene based on measured improvement in overall survival. This was the second drug approved for...

Scientists at the Theodor Boveri Institute at the University of Würzburg in Germany have potentially found a way to indirectly target the MYC oncogene—an elusive cancer therapy target. Martin Eilers and colleagues discovered...

Cancer treatment is undergoing significant developments and entering the new golden era of genomics which has true potentials for the promise of personalized medicine. Large-scale sequencing is changing our understanding of...

As the treatment of cancer shifts increasingly more toward oral therapies, patients are now partly responsible for when and how they take their medication. Despite the potential for increased absorption if taken with food, most...